Brain and behavior · 2024
The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Nana, Wang Ziya, Sun Dongren, Chen Hongxi, Zhou Hongyu
Аннотация
OBJECTIVE: The aim of this study is to ascertain whether COVID-19 Omicron infection is associated with exacerbations in these myasthenia gravis (MG) patients.
RESULT: In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID-19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID-19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, p = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post-infection was found to be 3.38 (95% CI 1.20-9.53, p = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID-19-infected MG patients (4.4% vs. 17.2%, p < 0.001).
CONCLUSION: The COVID-19 is the risk of MG exacerbation.
RESULT: In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID-19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID-19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, p = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post-infection was found to be 3.38 (95% CI 1.20-9.53, p = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID-19-infected MG patients (4.4% vs. 17.2%, p < 0.001).
CONCLUSION: The COVID-19 is the risk of MG exacerbation.